Literature DB >> 19256181

Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons.

David A Wilfret1, Brent T Baker, Elizabeth Palavecino, Cassandra Moran, Daniel K Benjamin.   

Abstract

BACKGROUND: The Centers for Disease Control and Prevention (CDC) monitors the occurrence of respiratory syncytial virus (RSV) in the United States and has historically reported on activity at the regional level. Prior to the 2007-2008 RSVseason, the CDC did not report seasonal RSV data for cities within North Carolina or for the state. The purpose of the present study is to characterize RSV seasonal activity within North Carolina and to determine the appropriate months in which at-risk children should receive prophylaxis.
METHODS: We prospectively collected RSV test data monthly over three seasons (fall through spring), from September 2003 through July 2006, from a diverse group of hospitals and a community pediatric practice located within five regions throughout North Carolina.
RESULTS: Approximately 14,000 laboratory tests, including 23.7% that were RSV positive, were evaluated over the three seasons, and RSV was detected within the state during all but three months of the study. Seasonal variation in the onset (October-November) of RSV activity and duration (six to seven months) of the RSV season according to the specified definition of seasonality was noted yearly within individual regions and among regions. On average over the study period, the greatest percentage of positive tests (33.8%) statewide occurred during January.
CONCLUSIONS: Our data suggest the RSV season in North Carolina is longer than the national average, and RSV epidemics persist during months that fall outside of those in which RSV prophylaxis is given to high-risk children. Guidelines on the administration of RSV prophylaxis should ideally be based on results of local RSV test data.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19256181      PMCID: PMC5482212     

Source DB:  PubMed          Journal:  N C Med J        ISSN: 0029-2559


  15 in total

1.  Continuous non-seasonal epidemic of respiratory syncytial virus infection in the southeast United States.

Authors:  D C Halstead; S G Jenkins
Journal:  South Med J       Date:  1998-05       Impact factor: 0.954

2.  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors: 
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

3.  Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.

Authors:  Rosalyn J Singleton; Dana Bruden; Lisa R Bulkow; Gilbert Varney; Jay C Butler
Journal:  Pediatr Infect Dis J       Date:  2006-12       Impact factor: 2.129

4.  Brief report: respiratory syncytial virus activity--United States, 2005-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2006-12-01       Impact factor: 17.586

5.  Substantial variability in community respiratory syncytial virus season timing.

Authors:  James A Mullins; Ashley C Lamonte; Joseph S Bresee; Larry J Anderson
Journal:  Pediatr Infect Dis J       Date:  2003-10       Impact factor: 2.129

6.  Respiratory syncytial virus laboratory surveillance and hospitalization trends in South Texas.

Authors:  Jaime Fergie; Kevin Purcell
Journal:  Pediatr Infect Dis J       Date:  2007-11       Impact factor: 2.129

7.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

8.  Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab.

Authors:  Jay Bauman; Mark Eggleston; Niki Oquist; Frank Malinoski
Journal:  South Med J       Date:  2007-07       Impact factor: 0.954

9.  Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.

Authors:  Shelah Leader; Kimmie Kohlhase
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406

10.  Influenza- and respiratory syncytial virus-associated morbidity and mortality in the nursing home population.

Authors:  Shelley E Ellis; Christopher S Coffey; Edward F Mitchel; Robert S Dittus; Marie R Griffin
Journal:  J Am Geriatr Soc       Date:  2003-06       Impact factor: 5.562

View more
  2 in total

1.  Epidemiology of respiratory syncytial virus infection in preterm infants.

Authors:  Bernhard Resch; Stefan Kurath; Paolo Manzoni
Journal:  Open Microbiol J       Date:  2011-12-30

2.  Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.

Authors:  Marina Treskova; Francisco Pozo-Martin; Stefan Scholz; Viktoria Schönfeld; Ole Wichmann; Thomas Harder
Journal:  Pharmacoeconomics       Date:  2021-01-19       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.